Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.

被引：3
|
作者：
Aguiar, Pedro Nazareth
Tadokoro, Hakaru
Barreto, Carmelia Maria Noia
Santoro, Ilka Lopes
De Mello, Ramon Andrade
Babiker, Hani M.
Avancha, Kiran
Lopes, Gilberto
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Dept Biomed Sci & Med, Faro Med Oncol & Res Ctr, Faro, Portugal
[3] HonorHlth Res Inst, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[4] HonorHlth Res Inst, Scottsdale, AZ USA
[5] Inst Canc Estado Sao Paulo, Clin Oncol, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9033
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
    Aguiar, Pedro, Jr.
    Perry, Luke A.
    Lopes, Gilberto L., Jr.
    [J]. LUNG CANCER MANAGEMENT, 2016, 5 (03) : 119 - 122
  • [2] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [4] Response to 'The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors'
    Ogale, S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (10) : 2140 - 2140
  • [5] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [6] Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Santoro, Ilka
    Babiker, Hani
    Avancha, Kiran
    Gutierres, Barbara
    Barreto, Carmelia
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S169 - S170
  • [7] Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.
    Pal, Sumanta K.
    Vanderwalde, Ari M.
    Szeto, Christopher
    Benz, Stephen Charles
    Sanborn, John Zachary
    Vaske, Charles Joseph
    Reddy, Sandeep K.
    Hamid, Omid
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [9] Immune checkpoint inhibitors' (ICI) efficacy according to PD-L1 expression for advanced or metastatic NSCLC: Systematic review and meta-analysis.
    Maciel, Glauber
    Carlos, Paula
    Murad Junior, Munir
    Araujo, Vania Eloisa
    Guerra, Augusto
    Acurcio, Francisco Assis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
12345